Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
Identifieur interne : 001D70 ( PubMed/Corpus ); précédent : 001D69; suivant : 001D71Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
Auteurs : Zhongyu Zhu ; Samitabh Chakraborti ; Yuxian He ; Anjeanette Roberts ; Tim Sheahan ; Xiaodong Xiao ; Lisa E. Hensley ; Ponraj Prabakaran ; Barry Rockx ; Igor A. Sidorov ; Davide Corti ; Leatrice Vogel ; Yang Feng ; Jae-Ouk Kim ; Lin-Fa Wang ; Ralph Baric ; Antonio Lanzavecchia ; Kristopher M. Curtis ; Gary J. Nabel ; Kanta Subbarao ; Shibo Jiang ; Dimiter S. DimitrovSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2007.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Binding, Competitive, Cell Fusion, Cross Reactions, Disease Models, Animal, Disease Outbreaks, Humans, Models, Biological, Models, Molecular, Mutagenesis, Nandiniidae (virology), Neutralization Tests, Protein Structure, Tertiary, Receptors, Cell Surface (chemistry), SARS Virus (immunology), SARS Virus (isolation & purification), SARS Virus (physiology), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Viral Proteins (metabolism), Virus Internalization, Virus Replication.
- MESH :
- chemical , chemistry : Receptors, Cell Surface.
- chemical , immunology : Antibodies, Monoclonal.
- epidemiology : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- isolation & purification : SARS Virus.
- chemical , metabolism : Viral Proteins.
- physiology : SARS Virus.
- virology : Nandiniidae, Severe Acute Respiratory Syndrome.
- Animals, Binding, Competitive, Cell Fusion, Cross Reactions, Disease Models, Animal, Disease Outbreaks, Humans, Models, Biological, Models, Molecular, Mutagenesis, Neutralization Tests, Protein Structure, Tertiary, Virus Internalization, Virus Replication.
Abstract
The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an independent animal-to-human transmission. The GD03 strain, which was isolated from an index patient of the second outbreak, was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which can potently neutralize isolates from the first outbreak. Here we report that two hmAbs, m396 and S230.15, potently neutralized GD03 and representative isolates from the first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16). These antibodies also protected mice challenged with the Urbani or recombinant viruses bearing the GD03 and SZ16 spike (S) glycoproteins. Both antibodies competed with the SARS-CoV receptor, ACE2, for binding to the receptor-binding domain (RBD), suggesting a mechanism of neutralization that involves interference with the SARS-CoV-ACE2 interaction. Two putative hot-spot residues in the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV spike that likely contribute to most of the m396-binding energy. Residues Ile-489 and Tyr-491 are highly conserved within the SARS-CoV spike, indicating a possible mechanism of the m396 cross-reactivity. Sequence analysis and mutagenesis data show that m396 might neutralize all zoonotic and epidemic SARS-CoV isolates with known sequences, except strains derived from bats. These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.
DOI: 10.1073/pnas.0701000104
PubMed: 17620608
Links to Exploration step
pubmed:17620608Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation><nlm:affiliation>Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Chakraborti, Samitabh" sort="Chakraborti, Samitabh" uniqKey="Chakraborti S" first="Samitabh" last="Chakraborti">Samitabh Chakraborti</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author><author><name sortKey="Sheahan, Tim" sort="Sheahan, Tim" uniqKey="Sheahan T" first="Tim" last="Sheahan">Tim Sheahan</name></author><author><name sortKey="Xiao, Xiaodong" sort="Xiao, Xiaodong" uniqKey="Xiao X" first="Xiaodong" last="Xiao">Xiaodong Xiao</name></author><author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name></author><author><name sortKey="Rockx, Barry" sort="Rockx, Barry" uniqKey="Rockx B" first="Barry" last="Rockx">Barry Rockx</name></author><author><name sortKey="Sidorov, Igor A" sort="Sidorov, Igor A" uniqKey="Sidorov I" first="Igor A" last="Sidorov">Igor A. Sidorov</name></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Feng, Yang" sort="Feng, Yang" uniqKey="Feng Y" first="Yang" last="Feng">Yang Feng</name></author><author><name sortKey="Kim, Jae Ouk" sort="Kim, Jae Ouk" uniqKey="Kim J" first="Jae-Ouk" last="Kim">Jae-Ouk Kim</name></author><author><name sortKey="Wang, Lin Fa" sort="Wang, Lin Fa" uniqKey="Wang L" first="Lin-Fa" last="Wang">Lin-Fa Wang</name></author><author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name></author><author><name sortKey="Curtis, Kristopher M" sort="Curtis, Kristopher M" uniqKey="Curtis K" first="Kristopher M" last="Curtis">Kristopher M. Curtis</name></author><author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J" last="Nabel">Gary J. Nabel</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17620608</idno><idno type="pmid">17620608</idno><idno type="doi">10.1073/pnas.0701000104</idno><idno type="wicri:Area/PubMed/Corpus">001D70</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D70</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation><nlm:affiliation>Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Chakraborti, Samitabh" sort="Chakraborti, Samitabh" uniqKey="Chakraborti S" first="Samitabh" last="Chakraborti">Samitabh Chakraborti</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author><author><name sortKey="Sheahan, Tim" sort="Sheahan, Tim" uniqKey="Sheahan T" first="Tim" last="Sheahan">Tim Sheahan</name></author><author><name sortKey="Xiao, Xiaodong" sort="Xiao, Xiaodong" uniqKey="Xiao X" first="Xiaodong" last="Xiao">Xiaodong Xiao</name></author><author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name></author><author><name sortKey="Rockx, Barry" sort="Rockx, Barry" uniqKey="Rockx B" first="Barry" last="Rockx">Barry Rockx</name></author><author><name sortKey="Sidorov, Igor A" sort="Sidorov, Igor A" uniqKey="Sidorov I" first="Igor A" last="Sidorov">Igor A. Sidorov</name></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Feng, Yang" sort="Feng, Yang" uniqKey="Feng Y" first="Yang" last="Feng">Yang Feng</name></author><author><name sortKey="Kim, Jae Ouk" sort="Kim, Jae Ouk" uniqKey="Kim J" first="Jae-Ouk" last="Kim">Jae-Ouk Kim</name></author><author><name sortKey="Wang, Lin Fa" sort="Wang, Lin Fa" uniqKey="Wang L" first="Lin-Fa" last="Wang">Lin-Fa Wang</name></author><author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name></author><author><name sortKey="Curtis, Kristopher M" sort="Curtis, Kristopher M" uniqKey="Curtis K" first="Kristopher M" last="Curtis">Kristopher M. Curtis</name></author><author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J" last="Nabel">Gary J. Nabel</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Binding, Competitive</term><term>Cell Fusion</term><term>Cross Reactions</term><term>Disease Models, Animal</term><term>Disease Outbreaks</term><term>Humans</term><term>Models, Biological</term><term>Models, Molecular</term><term>Mutagenesis</term><term>Nandiniidae (virology)</term><term>Neutralization Tests</term><term>Protein Structure, Tertiary</term><term>Receptors, Cell Surface (chemistry)</term><term>SARS Virus (immunology)</term><term>SARS Virus (isolation & purification)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Viral Proteins (metabolism)</term><term>Virus Internalization</term><term>Virus Replication</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Receptors, Cell Surface</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Nandiniidae</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Binding, Competitive</term><term>Cell Fusion</term><term>Cross Reactions</term><term>Disease Models, Animal</term><term>Disease Outbreaks</term><term>Humans</term><term>Models, Biological</term><term>Models, Molecular</term><term>Mutagenesis</term><term>Neutralization Tests</term><term>Protein Structure, Tertiary</term><term>Virus Internalization</term><term>Virus Replication</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an independent animal-to-human transmission. The GD03 strain, which was isolated from an index patient of the second outbreak, was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which can potently neutralize isolates from the first outbreak. Here we report that two hmAbs, m396 and S230.15, potently neutralized GD03 and representative isolates from the first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16). These antibodies also protected mice challenged with the Urbani or recombinant viruses bearing the GD03 and SZ16 spike (S) glycoproteins. Both antibodies competed with the SARS-CoV receptor, ACE2, for binding to the receptor-binding domain (RBD), suggesting a mechanism of neutralization that involves interference with the SARS-CoV-ACE2 interaction. Two putative hot-spot residues in the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV spike that likely contribute to most of the m396-binding energy. Residues Ile-489 and Tyr-491 are highly conserved within the SARS-CoV spike, indicating a possible mechanism of the m396 cross-reactivity. Sequence analysis and mutagenesis data show that m396 might neutralize all zoonotic and epidemic SARS-CoV isolates with known sequences, except strains derived from bats. These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17620608</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>29</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.</ArticleTitle><Pagination><MedlinePgn>12123-8</MedlinePgn></Pagination><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an independent animal-to-human transmission. The GD03 strain, which was isolated from an index patient of the second outbreak, was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which can potently neutralize isolates from the first outbreak. Here we report that two hmAbs, m396 and S230.15, potently neutralized GD03 and representative isolates from the first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16). These antibodies also protected mice challenged with the Urbani or recombinant viruses bearing the GD03 and SZ16 spike (S) glycoproteins. Both antibodies competed with the SARS-CoV receptor, ACE2, for binding to the receptor-binding domain (RBD), suggesting a mechanism of neutralization that involves interference with the SARS-CoV-ACE2 interaction. Two putative hot-spot residues in the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV spike that likely contribute to most of the m396-binding energy. Residues Ile-489 and Tyr-491 are highly conserved within the SARS-CoV spike, indicating a possible mechanism of the m396 cross-reactivity. Sequence analysis and mutagenesis data show that m396 might neutralize all zoonotic and epidemic SARS-CoV isolates with known sequences, except strains derived from bats. These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zhongyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakraborti</LastName><ForeName>Samitabh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Anjeanette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sheahan</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Hensley</LastName><ForeName>Lisa E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Prabakaran</LastName><ForeName>Ponraj</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rockx</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sidorov</LastName><ForeName>Igor A</ForeName><Initials>IA</Initials></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Leatrice</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae-Ouk</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lin-Fa</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Baric</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lanzavecchia</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Kristopher M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Nabel</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shibo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dimitrov</LastName><ForeName>Dimiter S</ForeName><Initials>DS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AI059443</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI059434</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI059136</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01CO12400</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI059136</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-CO-12400</GrantID><Acronym>CO</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002459" MajorTopicYN="N">Cell Fusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053827" MajorTopicYN="N">Nandiniidae</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17620608</ArticleId><ArticleId IdType="pii">0701000104</ArticleId><ArticleId IdType="doi">10.1073/pnas.0701000104</ArticleId><ArticleId IdType="pmc">PMC1924550</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14651994</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Jul 1;324(2):251-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15207612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Aug 15;326(1):140-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Sep;31(1):66-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15288616</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Sep 15;190(6):1119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15319862</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Oct;10(10):1774-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15504263</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Dec 5;330(1):8-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15527829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jan;79(1):503-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15596843</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2004 Dec;10(12):1062-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15606632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Feb;79(3):1635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15650189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Mol Ther. 2005 Apr;7(2):151-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15844623</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2005 Jul 22;333(1):186-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15939399</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Jul;11(7):1016-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16022774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Sep;79(18):11638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16140741</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005;2:73</Citation><ArticleIdList><ArticleId IdType="pubmed">16122388</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Dec;79(23):14909-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16282490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jan;80(2):891-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16378991</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2006 Mar 1;193(5):685-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 May;80(9):4211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16611880</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2006 May 15;176(10):6085-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16670317</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Jun 9;281(23):15829-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16597622</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2006;581:547-50</Citation><ArticleIdList><ArticleId IdType="pubmed">17037596</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001D70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17620608
|texte= Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17620608" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |